CM
BXRX

Caption Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Caption Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7
Closed -$68K – 1182
2019
Q4 		$68K Buy
+7
New +$59.7K ﹤0.01% 771

Other funds holding BXRX

NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Caption Management's BXRX Position: Q1 2020 in Review

Caption Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q1 2020, closing a stake of 7 shares — an estimated $68K sold.

Caption Management first reported a position in BXRX in Q4 2019 and held it in 1 quarter. The position peaked at $68K in Q4 2019. 47 funds tracked by Wall St. Rank hold BXRX as of Q1 2020.

  • Caption Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Caption Management sold 7 Baudax Bio, Inc. Common Stock shares in Q1 2020, an estimated $68K.
  • Caption Management first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Caption Management's Baudax Bio, Inc. Common Stock position peaked at $68K in Q4 2019.
  • 47 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q1 2020.

Based on Caption Management's 13F filing for Q1 2020, filed 15 May 2020.